Last €3.24 EUR
Change Today -0.032 / -0.98%
Volume 0.0
CBJ On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 1:54 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

cumberland pharmaceuticals (CBJ) Snapshot

Open
€3.27
Previous Close
€3.27
Day High
€3.27
Day Low
€3.20
52 Week High
07/26/13 - €4.32
52 Week Low
06/19/13 - €1.88
Market Cap
57.8M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
17.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CUMBERLAND PHARMACEUTICALS (CBJ)

cumberland pharmaceuticals (CBJ) Related Bloomberg News

View More Bloomberg News

cumberland pharmaceuticals (CBJ) Related Businessweek News

No Related Businessweek News Found

cumberland pharmaceuticals (CBJ) Details

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s principal products comprise Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. Its products also include Omeclamox-Pak, a triple therapy combination medication for the treatment of Helicobacter pylori infection and duodenal ulcer disease; and Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

96 Employees
Last Reported Date: 03/11/14
Founded in 1999

cumberland pharmaceuticals (CBJ) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $620.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $297.0K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $392.3K
Chief Commercial Officer, Senior Vice Preside...
Total Annual Compensation: $312.1K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $227.5K
Compensation as of Fiscal Year 2013.

cumberland pharmaceuticals (CBJ) Key Developments

Cumberland Pharmaceuticals, Inc., Annual General Meeting, Apr 15, 2014

Cumberland Pharmaceuticals, Inc., Annual General Meeting, Apr 15, 2014., at 10:00 Central Standard Time. Location: Centennial Boardroom, 2525 West End Avenue, Suite 950. Agenda: To elect two Class I Directors to serve until the 2017 Annual Meeting of Shareholders, or until their successors are duly elected and qualified; to ratify the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2014; to provide shareholders an opportunity to participate in an advisory vote on executive compensation; to transact such other business as may properly come before annual meeting or any postponement or adjournment of the meeting.

Cumberland Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Cumberland Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net revenue was $8.2 million, compared to $13.7 million for the prior year period. Net loss attributable to common shareholders was $1.5 million, or $0.08 per diluted share, compared to net income attributable to common shareholders of $1.8 million, or $0.09 per diluted share, for the same period in 2012. Operating loss was $2,472,077 compared to operating income of $3,252,993 for the same period a year ago. Loss before income taxes was $2,444,196 compared to income before income taxes of $3,286,168 for the same period a year ago. For the full year, the company reported net revenues were $32.0 million, compared with $48.9 million for 2012. Net loss attributable to common shareholders was $2.1 million, or $0.11 per diluted share, compared to net income of $5.8 million, or $0.30 per diluted share, for 2012. Operating loss was $3,801,338 compared to operating income of $8,818,102 for the same period a year ago. Loss before income taxes was $3,674,469 compared to income before income taxes of $9,050,982 for the same period a year ago. Net cash provided by operating activities was $746,126 compared to $7,135,182 for the same period a year ago. Additions to property and equipment were $97,412 compared to $464,893 for the same period a year ago. Additions to intangible assets were $7,462,080 compared to $2,071,926 for the same period a year ago.

Cumberland Pharmaceuticals, Inc. to Report Fiscal Year 2013 Results on Mar 04, 2014

Cumberland Pharmaceuticals, Inc. announced that they will report fiscal year 2013 results at 5:00 PM, Eastern Standard Time on Mar 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBJ:GR €3.24 EUR -0.032

CBJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acura Pharmaceuticals Inc $1.30 USD +0.015
Alexza Pharmaceuticals Inc $4.13 USD +0.03
Durect Corp $1.31 USD +0.02
Flamel Technologies SA $11.26 USD +0.66
Sucampo Pharmaceuticals Inc $6.77 USD -0.19
View Industry Companies
 

Industry Analysis

CBJ

Industry Average

Valuation CBJ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUMBERLAND PHARMACEUTICALS, please visit www.cumberlandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.